Chemotherapy-induced neuropathy (CIN) persists chronically for most individuals with breast cancer who develop the condition: A survey study

Chemotherapy-induced neuropathy (CIN) persists chronically for most individuals with breast cancer who develop the condition: A survey study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Chemotherapy-induced neuropathy (CIN) persists chronically for most individuals with breast cancer who develop the condition: A survey study Lise Worthen-Chaudhari, Maryam B. Lustberg, Bhillie D. Luciani, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8594232/v1 This work is licensed under a CC BY 4.0 License Status: Under Revision Version 1 posted 9 You are reading this latest preprint version Abstract Purpose A majority of individuals treated with taxane agents for breast cancer (BC) develop chemotherapy-induced neuropathy (CIN) yet questions remain regarding long-term prognosis of this neurologic complication. We sought to characterize CIN chronicity in terms of persistence rate, predictors, and neuromotor dysfunction. Methods We surveyed individuals with BC who developed CIN during taxane exposure at least 3 months prior. We calculated the proportion of survey respondents with/without chronic CIN symptoms and performed a sensitivity analysis, computing the largest and smallest possible rate of CIN chronicity given the number of non-respondents. Additionally, we analyzed predictors of chronicity (e.g., age, hgA1c level) and characterized the proportion of individuals with chronic sensory symptoms who also demonstrated neuromotor dysfunction. Results We surveyed two hundred and fifty-eight individuals (99.2% female). Mean(SD) age = 60.5(11.1); time since last taxane exposure = 3.25(2.38) years; and A1C = 5.64(0.607). Persistent CIN sensory symptoms were reported by 84.9% [95% CI 79.5%, 90.3%]. Accounting for both the non-response sensitivity analysis and statistical uncertainty, we calculate bounds for the CIN persistence rate to be no lower than 50.5% and no higher than 93.6%. Variables predictive of CIN chronicity included high A1C (p = 0.037). Variables not predictive included total chemotherapy dose (p = 0.8); race (white vs non-white, p = 0.4); age (p = 0.09); time since last taxane exposure < 6 years (p = 0.051). Among those with chronic CIN, 85% demonstrated quantifiable neuromotor dysfunction. Conclusion CIN symptoms persist chronically for most individuals (~ 85%) with breast cancer who develop the condition during taxane treatment. Novel interventions are needed to alleviate sensory symptoms and associated neuromotor dysfunction. Figures Figure 1 Introduction Individuals who have undergone cancer treatment report chemotherapy-induced neuropathy (CIN) as one of their highest, unmet priorities within survivorship, yet questions remain about scope of the problem among breast cancer survivors (Lustberg et al., 2023 ). It is commonly summarized that CIN resolves spontaneously within 3–6 months after conclusion of neurotoxic chemotherapy treatment for the majority of individuals who develop the condition from any type of cancer treatment (Maihöfner et al., 2021 ; Miltenburg & Boogerd, 2014 ; Seretny et al., 2014 ). However, a growing body of evidence indicates that CIN does not resolve for the majority of individuals with breast cancer who develop the condition (Bao et al., 2016 ; Cavaletti et al., 2015 ; Lavoie Smith et al., 2013 ; Mo et al., 2022 ; Seretny et al., 2014 ; Winters-Stone et al., 2017 ). If our common understanding that CIN spontaneously resolves for most individuals with breast cancer is incorrect then the need to prevent and rehabilitate CIN is more stark than formerly understood for this population. We performed this survey study to calculate CIN chronicity rate among individuals with breast cancer. Additionally, we sought to illuminate predictors and neuromotor consequences of chronic CIN in this population. Chemotherapy-induced neuropathy is a neurologic complication caused by exposure to cytotoxic chemotherapy drugs (e.g. paclitaxel, docetaxel) (Hu et al., 2019 ; Lavoie Smith et al., 2013 ). Once it develops, CIN can lead to discontinuation of treatment in the short-term (Song et al., 2017 ; Winters-Stone et al., 2023 ) and functional concerns in the long-term (Loprinzi et al., 2020 ; Lustberg et al., 2023 ; Song et al., 2017 ). Symptoms present as pain, numbness, tingling, burning (Tanay et al., 2017 ), and/or temperature sensitivity in the hands and feet (Jaggi & Singh, 2012 ; Li et al., 2021 ; Lustberg et al., 2023 ; Mezzanotte et al., 2022 ). In addition to uncomfortable sensory symptoms, CIN causes functional neuromotor deficits (Fino et al., 2019 ; Monfort et al., 2016 , 2017 , 2019 ) including increased risk of falling (Bao et al., 2016 ; Huang, 2019 ; Wechsler & Wood, 2021 ). Indirect evidence contradicts the belief that CIN resolves spontaneously among the majority of individuals with BC who develop the condition (Bao et al., 2016 ; Osmani et al., 2012 ; Postma et al., 1995 ; Winters-Stone et al., 2017 ). For example, Bao et al ( 2016 ) found that 51.2% of 296 post-menopausal women with breast cancer reported persistent and chronic CIN more than 5 years after discontinuing chemotherapy. Other datasets also suggest that CIN persists for a majority of those who develop it but do not calculate the rate of chronicity among individuals with BC, specifically (Osmani et al., 2012 ; Postma et al., 1995 ; Winters-Stone et al., 2017 ). We postulate that spontaneous resolution is atypical among individuals with breast cancer and hypothesize that a majority (> 50%) of individuals with BC who develop CIN symptoms during taxane-based treatment go on to experience the condition chronically (i.e., > 3 months post taxane-based chemotherapy discontinuation). Additionally, to expand understanding of predictors and functional consequences of CIN among individuals with BC, we analyzed predictors of chronicity (e.g., age, HgA1C level, time since chemotherapy completion) and quantified postural control dysfunction in a subset of survey respondents with chronic CIN. This study was performed as a secondary analysis of data collected for clinical trial NCT05114005 among individuals with breast cancer and CIN diagnoses (R21-AG068831). Methods This research protocol was approved by the Ohio State University (OSU) Institutional Review Board (IRB# 2015C0090). The full study protocol is described in Lantis et al. (Lantis et al., 2023 ) and was registered in ClinicalTrials.gov (NCT05114005); the present analysis examines recruitment and screening data from NCT05114005. Participant identification was comprised of three steps: electronic medical record screenings for taxane exposure plus documented patient report of CIN, contact and survey of CIN prevalence among eligible clients, and postural control data collections among an interested subset of survey respondents. Electronic Medical Record (EMR) Screening: As part of the study protocol, we queried patient records within OSU’s academic medical system to identify eligible participants living with breast cancer diagnosis who reported development of CIN symptoms during taxane-based chemotherapy exposure, were ≥ 40 years of age. We included any gender and individuals as young as 40 years of age because recent literature indicates that neither younger age nor gender are protective against development of CIN (Argyriou et al., 2025 ). From these records, we identified clients potentially eligible for participation in NCT05114005 who were treated within our medical center between the dates of March 11, 2014 and February 9, 2023. We used semantic search (i.e., text-based search of the record), to determine if the client reported neuropathy to a provider at any point during treatment or in the weeks following chemotherapy discontinuation (Fig. 1 ). Lastly, we used semantic search to exclude those with uncontrolled diabetes (hbA1c > 8.0) or neurologic disorder other than CIN (e.g. vestibular disorder, Parkinson Disease). Survey: We sought permission to contact clients who were deemed potentially eligible for NCT05114005 from their treating oncologist. To focus contact efforts among clients with whom providers were more recently familiar, we prioritized individuals who were between 0.25 and 6 years post chemotherapy completion, however, we included individuals up to 9 years post chemotherapy completion. Those cleared by the treating oncologist for contact were aggregated in a list sorted by medical record number and entered as record items within a secure Research Electronic Data Capture (REDCap) database (Nashville, TN). We assigned a pre-screen number in REDCap per potentially eligible individual and systematically attempted contact to determine (a) did CIN symptoms persist and (b) was the individual interested in an intervention trial targeting the persistent symptoms until recruitment for NCT05114005 was complete. Among those individuals who responded to our attempted contact and agreed to survey participation, we asked if CIN persisted as follows: “Your oncologist indicated that you experienced neuropathy symptoms during your treatment. Are you still experiencing neuropathy?” We documented contact results in the REDCap database. Statistical Analysis For our primary estimate of rate of chronicity, we computed the proportion of eligible participants who reported persistent CIN symptoms among those who responded to our survey. This approach assumes that responders were representative of the full eligible population (including non-responders) with respect to neuropathy. As a sensitivity analysis, we also computed proportions, assuming that all eligible non-respondents had neuropathy (i.e., maximum estimate) or did not have neuropathy (i.e., minimum estimate). Confidence intervals were computed via binomial test. Characteristics are expressed as mean (SD) and/or as median [min, max]. Prevalence over time was modeled using monotonically decreasing spline logistic regression. Neuromotor dysfunction among those with persistent sensory symptons: If contact was successful and responders reported persistent CIN symptoms at the time of contact, we invited responders to undergo an in-person screening of postural control (Reed et al., 2020 ; Worthen-Chaudhari et al., 2018 ). Briefly, screening involved participants standing bilaterally and quietly on a balance plate (Bertec Corp, Columbus, OH) for 30 seconds with eyes closed (QEC). Center of pressure (COP) variables of interest were calculated per Worthen-Chaudhari et al. ( 2018 ) (Worthen-Chaudhari et al., 2018 ), Prieto et al. ( 1996 ) (Prieto et al., 1996 ), and Roerdink et al. ( 2011 ) (Roerdink et al., 2011 ) using a custom MATLAB program (MathWorks, Natick, MA). We analyzed the number of respondents with CIN who demonstrated postural control function outside of the norm. As previously defined (Lantis et al., 2023 ), normative thresholds were estimated as outside of the 70% confidence interval (CI) of healthy, age-equivalent values (Worthen-Chaudhari et al., 2018 ) in variables that have proven to predict future fall risk (Maki et al., 1994 ; Worthen-Chaudhari et al., 2018 ) (i.e., COP ellipse area (COPa), medial-lateral variability (RMSml), medial-lateral velocity (COPvml)) and the estimated 95% CI in terms of COP complexity (SEI), a non-linear measure that has more recently been associated with neurologic challenge (Donker et al., 2007 , 2008 ; Quatman-Yates et al., 2015 ; Roerdink et al., 2011 ; Stins et al., 2009 ). Those that fell outside of postural control norms in any of the four measures (i.e., COPa, RMSml, COPvml, SEI) were deemed to have motor dysfunction associated with persistent, self-reported CIN symptoms. Results We identified 1966 records that potentially met eligibility criteria. Six hundred and fourteen clients were excluded due to deceased status, A1C levels > 8.0, or additional neural diagnosis such as vestibular disorder. The remaining 1352 records were categorized as having reported development of CIN to a provider and receiving a CIN diagnosis (748; 55.3%) or no report of CIN development during chemotherapy exposure (604; 44.7%). Of the individuals diagnosed with CIN at the time of treatment, we attempted contact with n = 258 for the purpose of surveying (a) current presence/absence of CIN symptoms and (b) interest in research-based nonpharmacologic options addressing these symptoms. One hundred and forty-six survey respondents confirmed that CIN persisted, while 26 reported that CIN had resolved completed or “did not bother them anymore”. Eighty-six individuals could not be contacted or declined to be surveyed. Survivor characteristics See Table 1 for details including mean(SD) and median[minimum, maximum] calculations per category. Among the overall cohort with whom we attempted contact before the survey ended (i.e., when recruitment goals for NCT05114005 were achieved), mean (SD) age was 60.5 (11.1) years; A1c level was 5.64 (0.61); and time since last taxane exposure was 3.25 (2.38) years. A majority were white (82.6%) and female (99.2%). Regarding taxane treatment, 41.9% were exposed to docetaxel only; 55.4% were exposed to paclitaxel only; and 2.7% were exposed to both docetaxel and paclitaxel. Among those receiving docetaxel only, mean (SD) overall exposure was 352 (97) mg/m 2 ; 20.2% received a dose reduction; and 0% received a dose increase. Of those receiving paclitaxel only, mean summed dosage was 721 (232) mg/m 2 ; 29.8% received a dose reduction; and 0.4% received a dose increase. Five individuals (1.9%) switched chemotherapy agents from docetaxel to paclitaxel while 2 switched from paclitaxel to docetaxel (0.8%). Table 1 further details medication dose and other characteristics reported by neuropathy subgroup as well as for the entire cohort. Finally, we analyzed differences between the 146 respondents with and 26 without chronic CIN. Only higher A1C levels predicted persistence of CIN for this cohort of individuals with BC who reported CIN during treatment (p = 0.037). Additionally, when considering those who received docetaxel only or paclitaxel only, with no combination of the two agents, those receiving docetaxel only showed a trend toward more frequent CIN persistence when compared to those receiving paclitaxel only (p = 0.077). No other factors predicted persistence of CIN including race, ethnicity, time since last taxol, age, or total taxane dose. Table 1 Characteristics of individuals with breast cancer and CIN grouped by survey response including age, time since last taxane exposure, race, ethnicity, A1c level, the taxane-based chemotherapy agent they were exposed to, and the total cumulative dosage of that agent they received. ^largest category v. other categories grouped, *p < 0.05. Neuropathy Persists (N = 146) Neuropathy Resolved (N = 26) No Response (N = 86) Overall (N = 258) Persists v Resolved (p value) Age (Years) Mean (SD) 61.8 (10.5) 58.3 (9.40) 58.8 (12.2) 60.5 (11.1) 0.091 Median [Min, Max] 62.0 [40.0, 85.0] 57.5 [42.0, 76.0] 58.0 [40.0, 90.0] 61.0 [40.0, 90.0] Time since last Taxol (Years) 0.051 Mean (SD) 3.06 (2.20) 3.23 (2.77) 3.60 (2.55) 3.25 (2.38) Median [Min, Max] 2.64 [0.26, 9.14] 2.29 (0.38, 8.46] 3.01 [0.25, 9.10] 2.77 [0.25, 9.14] Missing Count (%) 0 (0.0%) 0 (0.0%) 3 (3.5%) 3 (1.2%) Cancer stage I 62 (42.5%) 12 (46.2%) 29 (33.7%) 103 (39.9%) II 61 (41.8%) 7 (26.9%) 38 (44.2%) 106 (41.1%) III 17 (11.6%) 6 (23.1%) 15 (17.4%) 38 (14.7%) IV 2 (1.4%) 0 (0.0%) 2 (2.3%) 4 (1.6%) Metastatic disease 1 (0.7%) 1 (3.8%) 2 (2.3%) 4 (1.6%) Missing 3 (2.1%) 0 (0.0%) 0 (0.0%) 3 (1.2%) Race White 123 (84.2%) 24 (92.3%) 66 (76.7) 213 (82.6%) 0.376^ Black 15 (10.3%) 1 (3.8%) 12 (14.0%) 28 (10.9%) Asian/Pacific Islander 1 (0.7%) 0 (0%) 6 (7.0%) 7 (2.7%) American Indian / Alaskan 1 (0.7%) 0 (0%) 1 (1.2%) 2 (0.8%) Multiple 1 (0.7%) 1 (3.8%) 0 (0.0%) 2 (0.8%) Unknown/ Not reported 5 (3.4%) 0 (0%) 1 (1.2%) 6 (2.3%) Missing 0 (0.0%) 0 (0%) 0 (0.0%) 0 (0.0%) Ethnicity Latino / Hispanic 3 (2.1%) 1 (3.8%) 1 (1.2%) 5 (1.9%) 0.484^ Not Latino / Hispanic 143 (97.9%) 25 (96.2%) 84 (97.7%) 252 (97.7%) Unknown/ Not reported 0 (0%) 0 (0%) 1 (1.2%) 1 (0.4%) Missing 0 (0.0%) 0 (0%) 0 (0%) 0 (0%) A1c (%) Mean (SD) 5.65 (0.620) 5.40 (0.446) 5.70 (0.621) 5.64 (0.607) 0.037* Median [Min, Max] 5.60 [4.50, 7.70] 5.30 [4.80, 6.50] 5.60 [4.70, 7.80] 5.50 [4.50, 7.80] Missing Count (%) 27 (18.5%) 3 (11.5%) 22 (25.6%) 52 (20.2%) Taxanes Exposed To 0.077 Docetaxel (Doce) 63 (43.2%) 6 (23.1%) 39 (45.3%) 108 (41.9%) Paclitaxel (Pacli) 78 (53.4%) 19 (73.1%) 46 (53.5%) 143 (55.4%) Doce + Pacli 5 (3.4%) 1 (3.8%) 1 (1.2%) 7 (2.7%) Missing 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) Docetaxel Total Exposure (mg/m 2 ) 0.491 Mean (SD) 347 (73.5) 366 (117) 365 (132) 352 (97.0) Median [Min, Max] 345 [225, 450] 300 [285, 450 375 [195, 960] 345 [195, 960] Missing 0 0 3 3 (1.2%) Paclitaxel Total Exposure (mg/m 2 ) 0.245 Mean (SD) 745 (247) 659 (289) 708 (171) 721 (232) Median [Min, Max] 720 [72, 1440] 700 [80, 960] 700 [210, 960] 700 [72, 1440] Missing 5 0 1 6 (2.3%) Persistent sensory dysfunction estimate : CIN persisted for 146 (84.9%) of those who responded to our survey (responders) (95% confidence interval for population 79.5% to 90.3%). Our sensitivity analysis estimated a minimum and maximum possible count as follows: assuming all non-responders experienced resolution of CIN, then the minimum possible count of survivors with chronic sensorimotor neuropathy symptoms is 146 of 258 (56.6%; 95% CI 50.5% to 62.7%) and assuming all non-responders had persistent CIN, then the maximum possible count of survivors with chronic sensorimotor neuropathy symptoms is 232 of 258 (89.9%; 95% CI 86.2% to 93.6%). Accounting for both the non-response sensitivity analysis and statistical uncertainty, we calculate bounds for the CIN persistence rate to be 50.5% to 93.6%. Figure 1 depicts the estimated prevalence of persistent CIN as a function of years since last taxane exposure, based on respondents only and separately assuming that all non-respondents were neuropathy-free. Overall, changes in prevalence of persistence over time are not significant (respondents only p = 0.06, assuming all non-respondents are neuropathy-free p = 0.11). More specifically, in the first 5–6 years post treatment completion, CIN persistence does not appear to decrease with time. Beyond 6 years post-treatment there is insufficient data for reliable conclusions. Persistent neuromotor dysfunction estimate Among 146 respondents with chronic CIN, 59 performed in-person postural control screening. Balance measures were outside of normal healthy parameters for 86.4% (n = 51) and within normal parameters for 13.5% (n = 8). Postural sway values for those outside of normal healthy parameters are reported elsewhere (Lantis et al., 2023 ). Discussion Chronic CIN persisted for 84.9% [50.5%, 93.6%] of individuals with BC who were diagnosed with the condition during taxane-based chemotherapy treatment. Mean time since last taxane exposure for this cohort was more than 3 years. This result substantiates our hypothesis that CIN persists chronically, for many years, for most individuals with breast cancer who develop it. Time since last taxane exposure was not predictive of chronic CIN through at least 6 years post chemotherapy completions. However, A1C levels at the time of survey were predictive such that a higher A1C level was associated with increased risk of developing persistent CIN. Addi In addition to clarifying the rate of CIN persistence as higher than previously believed among individuals with BC, this study provides novel insights into the functional deficits associated with persistent CIN in this population. We calculated the rate of postural control deficits to be 85% [80%, 90%] among those who presented for in-person biomechanical testing. Therefore, of the ~ 85% of individuals in this cohort who reported persistent CIN, approximately 85% demonstrated quantifiable balance deficits in addition to patient-reported sensory symptoms. Because postural control dysfunction predicts increased fall risk, independent of sensory symptoms (Maki et al., 1994 ; Worthen-Chaudhari et al., 2018 ), this high rate of postural control dysfunction represents a potential neuromotor mechanism underlying the increased fall risk of individuals with CIN (Bao et al., 2016 ; Winters-Stone et al., 2023 ). Postural control deficits can be added to known functional consequences of CIN, in addition to known deficits in dual-task performance (Worthen-Chaudhari et al., 2024 ), gait characteristics (i.e., shorter and slower steps), chair-stand test, and short physical performance battery (Winters-Stone et al., 2017 ). There remains a need for more prospective studies characterizing the nature, scope, and mechanisms underlying functional deficits resulting from CIN. These should measure CIN symptoms using mixed-methods that combine patient-reported outcomes of sensation with quantitatively measured function. There are at least two ways in which the belief that CIN resolves spontaneously for most individuals with breast cancer may have developed. Firstly, very little literature has focused on breast cancer, specifically. Instead, most original research of CIN resolution rates after treatment tends to group CIN from different types of cancers together. For instance, a meta-analysis and systematic review by Seretny et al. ( 2014 ) pooled data from 4179 individuals who received chemotherapy of any type for any cancer diagnosis. In this meta-analysis, approximately half of those diagnosed with CIN reported that the condition improved between 3- and 6-months post chemotherapy completion. It is possible that results were assumed to generalize to individuals with BC. A second way that the belief of spontaneous CIN resolution may have developed is through misinterpretation of the original data. We found that two original data sets, from Postma et al ( 1995 ) and Osmani et al ( 2012 ), are cited to substantiate this interpretation. However, neither dataset supports the idea of spontaneous, complete resolution within 3 months. Postma et al. ( 1995 ) followed 7 individuals with BC; all 7 developed symptoms within their first course of high-dose paclitaxel. The authors followed 5 of these individuals for 9 months post chemotherapy termination, finding that 3 of 5 reported complete resolution of pain; all 5 reported changing CIN sensation in the 9 months following chemotherapy termination; however, none reported complete resolution of symptoms such as numbness, tingling, or functional deficits. Based on these results, Postma et al. ( 1995 ) conclude that CIN is “at least partially reversible” after discontinuation of paclitaxel exposure but the authors do not interpret their results to mean that spontaneous, complete resolution occurs for a majority within 6 months (Postma et al., 1995 ). The second dataset cited to substantiate the claim of CIN spontaneous resolution is published in Osmani et al. ( 2012 ) “Taxane-based neuropathy has a good long-term prognosis: a 1 to 13 year evaluation”. Within this dataset, only 6 of those diagnosed with CIN, or 14% or those surveyed, reported complete recovery within the 6 months following taxane-based treatment completion. Based on limited relative improvement, reported retrospectively by 86% of those with persistent CIN, the authors conclude that long-term prognosis for complete symptom resolution is good (Osmani et al., 2012 ) and infer that a majority experience spontaneous resolution. Of note, more than 80% of participants in this study were treated with docetaxel alone, yet results are generalized to all taxane-based CIN diagnoses. Interestingly, a close look at the data in these original reports substantiates our current estimate of CIN persistence among approximately 85%. Osmani et al ( 2012 ) report that 86% reported persistence of symptoms, albeit at a reduced severity to initial onset, and only 14% reported complete, spontaneous resolution of CIN. These original studies, cited to support the belief that CIN spontaneously resolves for a majority, ultimately support our current finding of chronic symptom persistence among approximately 85% of individuals with BC who developed CIN during chemotherapy treatment. Limitations While our study provides valuable insights into CIN persistence, limitations should be considered. For instance, our identification of those who reported CIN symptoms during treatment was limited to individuals detected via retrospective semantic search of electronic medical records. Because the text describing CIN in patient charts is not standardized across providers and years, the key terms describing CIN symptoms and diagnosis might have changed over the 9 year period within which we searched and between the different providers who we worked with to complete this survey. Therefore, our results may underestimate the incidence of those who developed CIN during treatment. Conversely, selection bias may have affected who responded to our survey, such that clients who felt better may have responded less frequently to our survey than those who felt worse, skewing estimates toward worse outcomes. Although this possibility is accounted for by our sensitivity analysis, it is important to note. Additionally, this data set is limited in that we confirm persistence of symptoms but lack the ability to confirm consistency of specific symptoms over the period of time between onset and time of survey. Postma et al ( 1995 ) provided initial evidence that neuropathic presentation of chronic CIN changes over time such that presence of symptomatology is consistent, but characteristics of symptoms may be dynamic. Additionally, more recent evidence suggests that neuropathic presentation of CIN might change over time, with one case report documenting a short period of resolution between 3 and 6 months post-chemotherapy completion followed by reemergence of tingling and coldness symptoms in the 2–6 years post chemotherapy completion (Papautsky et al.). Among individuals with BC, future research should use a repeated measures design over at least 5 years to characterize the changes in CIN symptoms post completion of chemotherapy. Despite these limitations, we found that most individuals with BC and CIN – almost 6 in 7 – experience persistent CIN symptoms its that do not spontaneously resolve within 3 months amd that a majority of these individuals also demonstrate neuromotor dysfunction. Given the impact of CIN on wellness in survivorship (Lustberg et al., 2023 ), there is a need to develop and implement targeted interventions to improve symptoms, function, and quality of life for affected individuals. Our findings reinforce the urgent need for routine long-term follow-up and neurorehabilitation strategies to address the burden of chronic CIN among BC survivors. More research is needed to characterize the dynamics of CIN symptoms through survivorship (Papautsky et al., in press; Postma et al., 1995 ) and determine best practices to prevent and mitigate this condition that sits at the intersection of oncologic, neurologic, and rehabilitative medicine. Declarations Ethical Approval and Consent to participate The study was approved by The Ohio State University Institutional Review Board (Ref: 2014C0177), and informed consent was obtained from all participants before the study, in accordance with the Declaration of Helsinki Consent for publication Authors grant Springer exclusive rights to publish, distribute, and archive the work in all media and confirm the work is original, not previously published, and doesn’t infringe on others’ rights. No protected health information or images are included in this publication. Competing interests The authors declare they have no competing interests. Funding This study was supported by National Institute on Aging (NIA) awards R21-AG068831 and R01-AG084676. Author Contribution PMS conceived of the study and led design of the study, data analysis in R, and interpretation of the data with LWC.LWC designed data acquisition, led manuscript writing, and contributed to design of the study and interpretation of the data with PMS.BL contributed to drafting and revising the manuscript as well as interpretation, validation, and collation of acquired data.MBL contributed to design of the study, interpretation of the data, and substantive revision of the work.MGM, SS, APD contributed to data acquisition, interpretation of the data, and substantive revision of the work.All authors read and approved the final manuscript. Acknowledgement We thank Kristin Lantis, Jackie Wilder, and Courtney Bland for data collection efforts on this project including survey administration. Data Availability Data are available in supplementary files associated with this manuscript. References Argyriou AA, Velasco R, Kalofonou F, Litsardopoulos P, Alemany M, Rikos D, Kalofonos HP, Bruna J. Gender and age effects on the incidence and severity of chemotherapy-induced neuropathic pain: A propensity score matching analysis. BMC Cancer. 2025;25(1):1193. https://doi.org/10.1186/s12885-025-14579-x . Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327–33. https://doi.org/10.1007/s10549-016-3939-0 . Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: An Underdiagnosed Clinical Entity? Am Soc Clin Oncol Educational Book. 2015;35:e553–60. https://doi.org/10.14694/EdBook_AM.2015.35.e553 . Donker SF, Ledebt A, Roerdink M, Savelsbergh GJ, Beek PJ. Children with cerebral palsy exhibit greater and more regular postural sway than typically developing children. Exp Brain Res. 2008;184(3):363–70. Donker SF, Roerdink M, Greven AJ, Beek PJ. Regularity of center-of-pressure trajectories depends on the amount of attention invested in postural control. Exp Brain Res. 2007;181(1):1–11. Fino PC, Horak FB, El-Gohary M, Guidarelli C, Medysky ME, Nagle SJ, Winters-Stone KM. Postural sway, falls, and self-reported neuropathy in aging female cancer survivors. Gait Posture. 2019;69:136–42. https://doi.org/10.1016/j.gaitpost.2019.01.025 . Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. Clin Cancer Res. 2019;25(21):6295–301. https://doi.org/10.1158/1078-0432.CCR-18-2152 . Huang MH. Screening and Examination of Fall Risk in Older Cancer Survivors. Rehabilitation Oncol. 2019;37(2):E7–9. https://doi.org/10.1097/01.REO.0000000000000166 . Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 2012;291(1–3):1–9. https://doi.org/10.1016/j.tox.2011.10.019 . Lantis K, Schnell P, Bland CR, Wilder J, Hock K, Vargo C, Glover NA, Hackney ME, Lustberg MB, Worthen-Chaudhari L. Biomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: Study protocol for a randomized controlled trial and preliminary baseline data. Trials. 2023;24(1):564. https://doi.org/10.1186/s13063-023-07554-z . Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res. 2013;22(10):2787–99. https://doi.org/10.1007/s11136-013-0379-8 . Li Y, Lustberg MB, Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers. 2021;13(4):766. https://doi.org/10.3390/cancers13040766 . Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325–48. https://doi.org/10.1200/JCO.20.01399 . Lustberg MB, Kuderer NM, Desai A, Bergerot C, Lyman GH. Mitigating long-term and delayed adverse events associated with cancer treatment: Implications for survivorship. Nat Rev Clin Oncol. 2023;20(8):527–42. https://doi.org/10.1038/s41571-023-00776-9 . Maihöfner C, Diel I, Tesch H, Quandel T, Baron R. Chemotherapy-induced peripheral neuropathy (CIPN): Current therapies and topical treatment option with high-concentration capsaicin. Support Care Cancer. 2021;29(8):4223–38. https://doi.org/10.1007/s00520-021-06042-x . Maki BE, Holliday PJ, Topper AK. A Prospective Study of Postural Balance and Risk of Falling in an Ambulatory and Independent Elderly Population. J Gerontology: Med Sci. 1994;49(2):72–84. Mezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, Lustberg MB. Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy. Curr Treat Options Oncol. 2022;23(1):29–42. https://doi.org/10.1007/s11864-021-00926-0 . Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014;40(7):872–82. https://doi.org/10.1016/j.ctrv.2014.04.004 . Mo H, Yan X, Zhao F, Teng Y, Sun X, Lv Z, Cao M, Zhao J, Song G, Pan B, Li H, Zhai J, Xu B, Ma F. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer. JAMA Netw Open. 2022;5(11):e2239788. https://doi.org/10.1001/jamanetworkopen.2022.39788 . Monfort S, Pan X, Loprinzi CL, Lustberg MB, Chaudhari AMW. Exploring the Roles of Central and Peripheral Nervous System Function in Gait Stability: Preliminary Insights from Cancer Survivors. Gait Posture. 2019;71:62–8. https://doi.org/10.1016/j.gaitpost.2019.04.002 . Monfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton MJ, Loprinzi CL, Chaudhari AMW, Lustberg MB. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Res Treat. 2017;164(1):69–77. https://doi.org/10.1007/s10549-017-4230-8 . Monfort S, Pan X, Patrick R, Singaravelu J, Loprinzi CL, Lustberg MB, Chaudhari AMW. Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study. Gait Posture. 2016;48:237–42. https://doi.org/10.1016/j.gaitpost.2016.06.011 . Osmani K, Vignes S, Aissi M, Wade F, Milani P, Lévy BI, Kubis N. Taxane-induced peripheral neuropathy has good long-term prognosis: A 1- to 13-year evaluation. J Neurol. 2012;259(9):1936–43. https://doi.org/10.1007/s00415-012-6442-5 . Papautsky EL, Lustberg MB, Worthen-Chaudhari LC. (in press). Change in Presentation of Chemotherapy-induced Neuropathy over a 6-year Period Post Treatment: A Case Study. Archives of Physical Medicine and Rehabilitation . Postma TJ, Vermorken JB, Liefting AJM, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6(5):489–94. https://www.sciencedirect.com/science/article/pii/S0923753419612366 . Prieto TE, Myklebust JB, Hoffmann RG, Lovett EG, Myklebust BM. Measures of postural steadiness differences between healthy young and elderly adults. Trans Biomedical Eng. 1996;43(9):965–6. Quatman-Yates CC, Bonnette MS, Hugentobler JA, Médé MB, Kiefer AW, Kurowski BG, Riley MA. Postconcussion postural sway variability changes in youth: The benefit of structural variability analyses. Pediatr Phys Ther. 2015;27(4):316. Reed CA, Chaudhari AM, Worthen-Chaudhari LC, Bigelow KE, Monfort SM. (2020). A new perspective on transient characteristics of quiet stance postural control. PLoS ONE, 15(8), e0237246. Roerdink M, Hlavackova P, Vuillerme N. Center-of-pressure regularity as a marker for attentional investment in postural control: A comparison between sitting and standing postures. Hum Mov Sci. 2011;30(2):203–12. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. PAIN®. 2014;155(12):2461–70. https://doi.org/10.1016/j.pain.2014.09.020 . Song SJ, Min J, Suh SY, Jung SH, Hahn HJ, Im S-A, Lee J-Y. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer. 2017;25(7):2241–8. https://doi.org/10.1007/s00520-017-3631-x . Stins JF, Michielsen ME, Roerdink M, Beek PJ. Sway regularity reflects attentional involvement in postural control: Effects of expertise, vision and cognition. Gait Posture. 2009;30(1):106–9. Tanay MAL, Armes J, Ream E. (2017). The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: A qualitative thematic synthesis. Eur J Cancer Care, 26(5), e12443. Wechsler S, Wood L. The Effect of Chemotherapy on Balance, Gait, and Falls Among Cancer Survivors: A Scoping Review. Rehabilitation Oncol. 2021;39(1):6–22. https://doi.org/10.1097/01.REO.0000000000000238 . Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;35(23):2604. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549452/ . Winters-Stone KM, Krasnow SM, Horak FB, Mancini M, Cameron MH, Dieckmann NF, Stoyles SA, Roeland EJ. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: The PATTERN observational study protocol (NCT05790538). BMC Cancer. 2023;23(1):1087. https://doi.org/10.1186/s12885-023-11546-2 . Worthen-Chaudhari L, Crasta JE, Schnell PM, Lantis K, Martis J, WIlder J, Bland CR, Hackney ME, Lustberg MB. (2024). Neurologic Dance Training (NDT) and home exercise improve motor-cognitive integration comparably, but differently, among breast cancer survivors with chemotherapy-induced neuropathy: Initial results of a randomized, controlled clinical trial. J Alzheimer’s Disease, 13872877241291440. Worthen-Chaudhari L, Monfort S, Bland C, Pan X, Chaudhari A. Characterizing within-subject variability in quantified measures of balance control: A cohort study. Gait Posture. 2018;64:141–6. Additional Declarations No competing interests reported. Supplementary Files datapersistencepublic.csv cipnpersistencepublicanalysiscode.qmd Cite Share Download PDF Status: Under Revision Version 1 posted Editorial decision: Revision requested 14 Apr, 2026 Reviews received at journal 15 Mar, 2026 Reviewers agreed at journal 01 Mar, 2026 Reviewers agreed at journal 28 Feb, 2026 Reviewers agreed at journal 26 Jan, 2026 Reviewers invited by journal 21 Jan, 2026 Editor assigned by journal 20 Jan, 2026 Submission checks completed at journal 20 Jan, 2026 First submitted to journal 13 Jan, 2026 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8594232","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":580756184,"identity":"eeb33a65-4e19-4b69-9bbc-746ccd2b1c38","order_by":0,"name":"Lise Worthen-Chaudhari","email":"data:image/png;base64,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","orcid":"","institution":"The Ohio State University","correspondingAuthor":true,"prefix":"","firstName":"Lise","middleName":"","lastName":"Worthen-Chaudhari","suffix":""},{"id":580756185,"identity":"9bce6de0-4cfa-4ab2-80da-86cc5184cd7a","order_by":1,"name":"Maryam B. Lustberg","email":"","orcid":"","institution":"Yale University","correspondingAuthor":false,"prefix":"","firstName":"Maryam","middleName":"B.","lastName":"Lustberg","suffix":""},{"id":580756186,"identity":"dd778357-aebb-4b44-95de-5ca48471d17b","order_by":2,"name":"Bhillie D. Luciani","email":"","orcid":"","institution":"The Ohio State University","correspondingAuthor":false,"prefix":"","firstName":"Bhillie","middleName":"D.","lastName":"Luciani","suffix":""},{"id":580756187,"identity":"8f454a06-1ca3-48c0-95de-038bc33bf913","order_by":3,"name":"Margaret E. Gatti-Mays","email":"","orcid":"","institution":"The Ohio State University","correspondingAuthor":false,"prefix":"","firstName":"Margaret","middleName":"E.","lastName":"Gatti-Mays","suffix":""},{"id":580756188,"identity":"d6b836b2-a33f-45b3-899d-d536e5bba60c","order_by":4,"name":"Sagar D. Sardesai","email":"","orcid":"","institution":"The Ohio State University","correspondingAuthor":false,"prefix":"","firstName":"Sagar","middleName":"D.","lastName":"Sardesai","suffix":""},{"id":580756189,"identity":"134474ea-f11b-4561-9d51-3cd6976cbdd1","order_by":5,"name":"Ashley P. Davenport","email":"","orcid":"","institution":"The Ohio State University","correspondingAuthor":false,"prefix":"","firstName":"Ashley","middleName":"P.","lastName":"Davenport","suffix":""},{"id":580756190,"identity":"1cc5ddc5-707b-48f9-9af6-3fb65bf6da92","order_by":6,"name":"Patrick M. Schnell","email":"","orcid":"","institution":"The Ohio State University","correspondingAuthor":false,"prefix":"","firstName":"Patrick","middleName":"M.","lastName":"Schnell","suffix":""}],"badges":[],"createdAt":"2026-01-13 16:23:52","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8594232/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8594232/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":101355396,"identity":"6a220b65-608e-4aef-83ed-d3a2b9d55164","added_by":"auto","created_at":"2026-01-28 20:14:02","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":66903,"visible":true,"origin":"","legend":"\u003cp\u003eEstimated prevalence of persistent CIN over time among patients exposed to taxanes at least three months prior and having reported neuropathy development during taxol treatment. Curves and shaded regions indicate estimated prevalence and 95% confidence intervals from logistic regression with monotonically decreasing splines. Bars indicate counts of patients with (top) and without (bottom) neuropathy, not related to vertical axis scale. Changes in prevalence over time are not statistically significant (respondents only p =0.06).\u003c/p\u003e","description":"","filename":"Picture1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-8594232/v1/e69ba1be7142d93a1ebf82e3.jpg"},{"id":101397867,"identity":"415cd5ed-fb0e-4055-afce-1d1e6acc13f5","added_by":"auto","created_at":"2026-01-29 09:37:47","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":942638,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8594232/v1/e2c9d7a3-3c40-49b5-9475-426bfe88c5e3.pdf"},{"id":101355397,"identity":"e47b1640-7729-448c-8f64-f0412d0917b6","added_by":"auto","created_at":"2026-01-28 20:14:02","extension":"csv","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":33682,"visible":true,"origin":"","legend":"","description":"","filename":"datapersistencepublic.csv","url":"https://assets-eu.researchsquare.com/files/rs-8594232/v1/c747bac8700412a642ac43a8.csv"},{"id":101355398,"identity":"442a76e7-96a2-4714-8ca7-f8e7b946124c","added_by":"auto","created_at":"2026-01-28 20:14:03","extension":"qmd","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":8611,"visible":true,"origin":"","legend":"","description":"","filename":"cipnpersistencepublicanalysiscode.qmd","url":"https://assets-eu.researchsquare.com/files/rs-8594232/v1/045eeb8a900e1c382a7fb268.qmd"}],"financialInterests":"No competing interests reported.","formattedTitle":"Chemotherapy-induced neuropathy (CIN) persists chronically for most individuals with breast cancer who develop the condition: A survey study","fulltext":[{"header":"Introduction","content":"\u003cp\u003eIndividuals who have undergone cancer treatment report chemotherapy-induced neuropathy (CIN) as one of their highest, unmet priorities within survivorship, yet questions remain about scope of the problem among breast cancer survivors (Lustberg et al., \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). It is commonly summarized that CIN resolves spontaneously within 3\u0026ndash;6 months after conclusion of neurotoxic chemotherapy treatment for the majority of individuals who develop the condition from any type of cancer treatment (Maih\u0026ouml;fner et al., \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Miltenburg \u0026amp; Boogerd, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e2014\u003c/span\u003e; Seretny et al., \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e2014\u003c/span\u003e). However, a growing body of evidence indicates that CIN does not resolve for the majority of individuals with breast cancer who develop the condition (Bao et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Cavaletti et al., \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2015\u003c/span\u003e; Lavoie Smith et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2013\u003c/span\u003e; Mo et al., \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Seretny et al., \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e2014\u003c/span\u003e; Winters-Stone et al., \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e2017\u003c/span\u003e). If our common understanding that CIN spontaneously resolves for most individuals with breast cancer is incorrect then the need to prevent and rehabilitate CIN is more stark than formerly understood for this population. We performed this survey study to calculate CIN chronicity rate among individuals with breast cancer. Additionally, we sought to illuminate predictors and neuromotor consequences of chronic CIN in this population.\u003c/p\u003e \u003cp\u003eChemotherapy-induced neuropathy is a neurologic complication caused by exposure to cytotoxic chemotherapy drugs (e.g. paclitaxel, docetaxel) (Hu et al., \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e2019\u003c/span\u003e; Lavoie Smith et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2013\u003c/span\u003e). Once it develops, CIN can lead to discontinuation of treatment in the short-term (Song et al., \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e2017\u003c/span\u003e; Winters-Stone et al., \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e2023\u003c/span\u003e) and functional concerns in the long-term (Loprinzi et al., \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e2020\u003c/span\u003e; Lustberg et al., \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Song et al., \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e2017\u003c/span\u003e). Symptoms present as pain, numbness, tingling, burning (Tanay et al., \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e2017\u003c/span\u003e), and/or temperature sensitivity in the hands and feet (Jaggi \u0026amp; Singh, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e2012\u003c/span\u003e; Li et al., \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Lustberg et al., \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Mezzanotte et al., \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). In addition to uncomfortable sensory symptoms, CIN causes functional neuromotor deficits (Fino et al., \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e2019\u003c/span\u003e; Monfort et al., \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e2016\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e2017\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e2019\u003c/span\u003e) including increased risk of falling (Bao et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Huang, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e2019\u003c/span\u003e; Wechsler \u0026amp; Wood, \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e2021\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eIndirect evidence contradicts the belief that CIN resolves spontaneously among the majority of individuals with BC who develop the condition (Bao et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Osmani et al., \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e2012\u003c/span\u003e; Postma et al., \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e1995\u003c/span\u003e; Winters-Stone et al., \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e2017\u003c/span\u003e). For example, Bao et al (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2016\u003c/span\u003e) found that 51.2% of 296 post-menopausal women with breast cancer reported persistent and chronic CIN more than 5 years after discontinuing chemotherapy. Other datasets also suggest that CIN persists for a majority of those who develop it but do not calculate the rate of chronicity among individuals with BC, specifically (Osmani et al., \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e2012\u003c/span\u003e; Postma et al., \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e1995\u003c/span\u003e; Winters-Stone et al., \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e2017\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eWe postulate that spontaneous resolution is atypical among individuals with breast cancer and hypothesize that a majority (\u0026gt;\u0026thinsp;50%) of individuals with BC who develop CIN symptoms during taxane-based treatment go on to experience the condition chronically (i.e., \u0026gt;\u0026thinsp;3 months post taxane-based chemotherapy discontinuation). Additionally, to expand understanding of predictors and functional consequences of CIN among individuals with BC, we analyzed predictors of chronicity (e.g., age, HgA1C level, time since chemotherapy completion) and quantified postural control dysfunction in a subset of survey respondents with chronic CIN. This study was performed as a secondary analysis of data collected for clinical trial NCT05114005 among individuals with breast cancer and CIN diagnoses (R21-AG068831).\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e This research protocol was approved by the Ohio State University (OSU) Institutional Review Board (IRB# 2015C0090). The full study protocol is described in Lantis et al. (Lantis et al., \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e2023\u003c/span\u003e) and was registered in ClinicalTrials.gov (NCT05114005); the present analysis examines recruitment and screening data from NCT05114005. Participant identification was comprised of three steps: electronic medical record screenings for taxane exposure plus documented patient report of CIN, contact and survey of CIN prevalence among eligible clients, and postural control data collections among an interested subset of survey respondents.\u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eElectronic Medical Record (EMR) Screening:\u003c/h2\u003e \u003cp\u003e As part of the study protocol, we queried patient records within OSU\u0026rsquo;s academic medical system to identify eligible participants living with breast cancer diagnosis who reported development of CIN symptoms during taxane-based chemotherapy exposure, were \u0026ge;\u0026thinsp;40 years of age. We included any gender and individuals as young as 40 years of age because recent literature indicates that neither younger age nor gender are protective against development of CIN (Argyriou et al., \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2025\u003c/span\u003e). From these records, we identified clients potentially eligible for participation in NCT05114005 who were treated within our medical center between the dates of March 11, 2014 and February 9, 2023. We used semantic search (i.e., text-based search of the record), to determine if the client reported neuropathy to a provider at any point during treatment or in the weeks following chemotherapy discontinuation (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Lastly, we used semantic search to exclude those with uncontrolled diabetes (hbA1c\u0026thinsp;\u0026gt;\u0026thinsp;8.0) or neurologic disorder other than CIN (e.g. vestibular disorder, Parkinson Disease).\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eSurvey:\u003c/h3\u003e\n\u003cp\u003eWe sought permission to contact clients who were deemed potentially eligible for NCT05114005 from their treating oncologist. To focus contact efforts among clients with whom providers were more recently familiar, we prioritized individuals who were between 0.25 and 6 years post chemotherapy completion, however, we included individuals up to 9 years post chemotherapy completion. Those cleared by the treating oncologist for contact were aggregated in a list sorted by medical record number and entered as record items within a secure Research Electronic Data Capture (REDCap) database (Nashville, TN). We assigned a pre-screen number in REDCap per potentially eligible individual and systematically attempted contact to determine (a) did CIN symptoms persist and (b) was the individual interested in an intervention trial targeting the persistent symptoms until recruitment for NCT05114005 was complete. Among those individuals who responded to our attempted contact and agreed to survey participation, we asked if CIN persisted as follows: \u0026ldquo;Your oncologist indicated that you experienced neuropathy symptoms during your treatment. Are you still experiencing neuropathy?\u0026rdquo; We documented contact results in the REDCap database.\u003c/p\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eStatistical Analysis\u003c/h2\u003e \u003cp\u003eFor our primary estimate of rate of chronicity, we computed the proportion of eligible participants who reported persistent CIN symptoms among those who responded to our survey. This approach assumes that responders were representative of the full eligible population (including non-responders) with respect to neuropathy. As a sensitivity analysis, we also computed proportions, assuming that all eligible non-respondents had neuropathy (i.e., maximum estimate) or did not have neuropathy (i.e., minimum estimate). Confidence intervals were computed via binomial test. Characteristics are expressed as mean (SD) and/or as median [min, max]. Prevalence over time was modeled using monotonically decreasing spline logistic regression.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eNeuromotor dysfunction among those with persistent sensory symptons:\u003c/h3\u003e\n\u003cp\u003eIf contact was successful and responders reported persistent CIN symptoms at the time of contact, we invited responders to undergo an in-person screening of postural control (Reed et al., \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e2020\u003c/span\u003e; Worthen-Chaudhari et al., \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e2018\u003c/span\u003e). Briefly, screening involved participants standing bilaterally and quietly on a balance plate (Bertec Corp, Columbus, OH) for 30 seconds with eyes closed (QEC). Center of pressure (COP) variables of interest were calculated per Worthen-Chaudhari et al. (\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e2018\u003c/span\u003e) (Worthen-Chaudhari et al., \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e2018\u003c/span\u003e), Prieto et al. (\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e1996\u003c/span\u003e) (Prieto et al., \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e1996\u003c/span\u003e), and Roerdink et al. (\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e2011\u003c/span\u003e) (Roerdink et al., \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e2011\u003c/span\u003e) using a custom MATLAB program (MathWorks, Natick, MA).\u003c/p\u003e \u003cp\u003eWe analyzed the number of respondents with CIN who demonstrated postural control function outside of the norm. As previously defined (Lantis et al., \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e2023\u003c/span\u003e), normative thresholds were estimated as outside of the 70% confidence interval (CI) of healthy, age-equivalent values (Worthen-Chaudhari et al., \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e2018\u003c/span\u003e) in variables that have proven to predict future fall risk (Maki et al., \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e1994\u003c/span\u003e; Worthen-Chaudhari et al., \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e2018\u003c/span\u003e) (i.e., COP ellipse area (COPa), medial-lateral variability (RMSml), medial-lateral velocity (COPvml)) and the estimated 95% CI in terms of COP complexity (SEI), a non-linear measure that has more recently been associated with neurologic challenge (Donker et al., \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2007\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2008\u003c/span\u003e; Quatman-Yates et al., \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e2015\u003c/span\u003e; Roerdink et al., \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e2011\u003c/span\u003e; Stins et al., \u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e2009\u003c/span\u003e). Those that fell outside of postural control norms in any of the four measures (i.e., COPa, RMSml, COPvml, SEI) were deemed to have motor dysfunction associated with persistent, self-reported CIN symptoms.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eWe identified 1966 records that potentially met eligibility criteria. Six hundred and fourteen clients were excluded due to deceased status, A1C levels\u0026thinsp;\u0026gt;\u0026thinsp;8.0, or additional neural diagnosis such as vestibular disorder. The remaining 1352 records were categorized as having reported development of CIN to a provider and receiving a CIN diagnosis (748; 55.3%) or no report of CIN development during chemotherapy exposure (604; 44.7%). Of the individuals diagnosed with CIN at the time of treatment, we attempted contact with n\u0026thinsp;=\u0026thinsp;258 for the purpose of surveying (a) current presence/absence of CIN symptoms and (b) interest in research-based nonpharmacologic options addressing these symptoms. One hundred and forty-six survey respondents confirmed that CIN persisted, while 26 reported that CIN had resolved completed or \u0026ldquo;did not bother them anymore\u0026rdquo;. Eighty-six individuals could not be contacted or declined to be surveyed.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eSurvivor characteristics\u003c/strong\u003e \u003cp\u003eSee Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e for details including mean(SD) and median[minimum, maximum] calculations per category. Among the overall cohort with whom we attempted contact\u003c/p\u003e \u003c/p\u003e \u003cp\u003ebefore the survey ended (i.e., when recruitment goals for NCT05114005 were achieved), mean (SD) age was 60.5 (11.1) years; A1c level was 5.64 (0.61); and time since last taxane exposure was 3.25 (2.38) years. A majority were white (82.6%) and female (99.2%). Regarding taxane treatment, 41.9% were exposed to docetaxel only; 55.4% were exposed to paclitaxel only; and 2.7% were exposed to both docetaxel and paclitaxel. Among those receiving docetaxel only, mean (SD) overall exposure was 352 (97) mg/m\u003csup\u003e2\u003c/sup\u003e; 20.2% received a dose reduction; and 0% received a dose increase. Of those receiving paclitaxel only, mean summed dosage was 721 (232) mg/m\u003csup\u003e2\u003c/sup\u003e; 29.8% received a dose reduction; and 0.4% received a dose increase. Five individuals (1.9%) switched chemotherapy agents from docetaxel to paclitaxel while 2 switched from paclitaxel to docetaxel (0.8%). Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e further details medication dose and other characteristics reported by neuropathy subgroup as well as for the entire cohort.\u003c/p\u003e \u003cp\u003eFinally, we analyzed differences between the 146 respondents with and 26 without chronic CIN. Only higher A1C levels predicted persistence of CIN for this cohort of individuals with BC who reported CIN during treatment (p\u0026thinsp;=\u0026thinsp;0.037). Additionally, when considering those who received docetaxel only or paclitaxel only, with no combination of the two agents, those receiving docetaxel only showed a trend toward more frequent CIN persistence when compared to those receiving paclitaxel only (p\u0026thinsp;=\u0026thinsp;0.077). No other factors predicted persistence of CIN including race, ethnicity, time since last taxol, age, or total taxane dose.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eCharacteristics of individuals with breast cancer and CIN grouped by survey response including age, time since last taxane exposure, race, ethnicity, A1c level, the taxane-based chemotherapy agent they were exposed to, and the total cumulative dosage of that agent they received. ^largest category v. other categories grouped, \u003cb\u003e*p\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/b\u003e\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"6\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNeuropathy Persists\u003c/p\u003e \u003cp\u003e(N\u0026thinsp;=\u0026thinsp;146)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNeuropathy Resolved\u003c/p\u003e \u003cp\u003e(N\u0026thinsp;=\u0026thinsp;26)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNo Response (N\u0026thinsp;=\u0026thinsp;86)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eOverall\u003c/p\u003e \u003cp\u003e(N\u0026thinsp;=\u0026thinsp;258)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003ePersists v Resolved (p value)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge (Years)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e61.8 (10.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e58.3 (9.40)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e58.8 (12.2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e60.5 (11.1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.091\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian [Min, Max]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e62.0 [40.0, 85.0]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e57.5 [42.0, 76.0]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e58.0 [40.0, 90.0]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e61.0 [40.0, 90.0]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTime since last Taxol (Years)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.051\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3.06 (2.20)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3.23 (2.77)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.60 (2.55)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3.25 (2.38)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian [Min, Max]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.64 [0.26, 9.14]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.29 (0.38, 8.46]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.01 [0.25, 9.10]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2.77 [0.25, 9.14]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMissing Count (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3 (3.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3 (1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCancer stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e62 (42.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12 (46.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e29 (33.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e103 (39.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e61 (41.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e7 (26.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e38 (44.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e106 (41.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e17 (11.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (23.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e15 (17.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e38 (14.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2 (1.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2 (2.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4 (1.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMetastatic disease\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (3.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2 (2.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4 (1.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMissing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (2.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3 (1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRace\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWhite\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e123 (84.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e24 (92.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e66 (76.7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e213 (82.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.376^\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBlack\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e15 (10.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (3.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e12 (14.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e28 (10.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAsian/Pacific Islander\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e6 (7.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e7 (2.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAmerican Indian / Alaskan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2 (0.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMultiple\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1 (0.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (3.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2 (0.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUnknown/ Not reported\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5 (3.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e6 (2.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMissing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEthnicity\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLatino / Hispanic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3 (2.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (3.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e5 (1.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.484^\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNot Latino / Hispanic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e143 (97.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25 (96.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e84 (97.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e252 (97.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eUnknown/ Not reported\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1 (0.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMissing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0 (0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eA1c (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.65 (0.620)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.40 (0.446)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.70 (0.621)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e5.64 (0.607)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.037*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian [Min, Max]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5.60 [4.50, 7.70]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e5.30 [4.80, 6.50]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e5.60 [4.70, 7.80]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e5.50 [4.50, 7.80]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMissing Count (%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e27 (18.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3 (11.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e22 (25.6%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e52 (20.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTaxanes Exposed To\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.077\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDocetaxel (Doce)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e63 (43.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6 (23.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e39 (45.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e108 (41.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePaclitaxel (Pacli)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e78 (53.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19 (73.1%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e46 (53.5%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e143 (55.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDoce\u0026thinsp;+\u0026thinsp;Pacli\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5 (3.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1 (3.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1 (1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e7 (2.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMissing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0 (0.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDocetaxel Total Exposure (mg/m\u003csup\u003e2\u003c/sup\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.491\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e347 (73.5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e366 (117)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e365 (132)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e352 (97.0)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian [Min, Max]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e345 [225, 450]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e300 [285, 450\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e375 [195, 960]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e345 [195, 960]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMissing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3 (1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePaclitaxel Total Exposure (mg/m\u003csup\u003e2\u003c/sup\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.245\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMean (SD)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e745 (247)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e659 (289)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e708 (171)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e721 (232)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMedian [Min, Max]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e720 [72, 1440]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e700 [80, 960]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e700 [210, 960]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e700 [72, 1440]\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMissing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e6 (2.3%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003ePersistent sensory dysfunction estimate\u003c/em\u003e: CIN persisted for 146 (84.9%) of those who responded to our survey (responders) (95% confidence interval for population 79.5% to 90.3%). Our sensitivity analysis estimated a minimum and maximum possible count as follows: assuming all non-responders experienced resolution of CIN, then the minimum possible count of survivors with chronic sensorimotor neuropathy symptoms is 146 of 258 (56.6%; 95% CI 50.5% to 62.7%) and assuming all non-responders had persistent CIN, then the maximum possible count of survivors with chronic sensorimotor neuropathy symptoms is 232 of 258 (89.9%; 95% CI 86.2% to 93.6%). Accounting for both the non-response sensitivity analysis and statistical uncertainty, we calculate bounds for the CIN persistence rate to be 50.5% to 93.6%. Figure\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e depicts the estimated prevalence of persistent CIN as a function of years since last taxane exposure, based on respondents only and separately assuming that all non-respondents were neuropathy-free. Overall, changes in prevalence of persistence over time are not significant (respondents only p\u0026thinsp;=\u0026thinsp;0.06, assuming all non-respondents are neuropathy-free p\u0026thinsp;=\u0026thinsp;0.11). More specifically, in the first 5\u0026ndash;6 years post treatment completion, CIN persistence does not appear to decrease with time. Beyond 6 years post-treatment there is insufficient data for reliable conclusions.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003ePersistent neuromotor dysfunction estimate\u003c/strong\u003e \u003cp\u003eAmong 146 respondents with chronic CIN, 59 performed in-person postural control screening. Balance measures were outside of normal healthy parameters for 86.4% (n\u0026thinsp;=\u0026thinsp;51) and within normal parameters for 13.5% (n\u0026thinsp;=\u0026thinsp;8). Postural sway values for those outside of normal healthy parameters are reported elsewhere (Lantis et al., \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e2023\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eChronic CIN persisted for 84.9% [50.5%, 93.6%] of individuals with BC who were diagnosed with the condition during taxane-based chemotherapy treatment. Mean time since last taxane exposure for this cohort was more than 3 years. This result substantiates our hypothesis that CIN persists chronically, for many years, for most individuals with breast cancer who develop it. Time since last taxane exposure was not predictive of chronic CIN through at least 6 years post chemotherapy completions. However, A1C levels at the time of survey were predictive such that a higher A1C level was associated with increased risk of developing persistent CIN. Addi\u003c/p\u003e \u003cp\u003eIn addition to clarifying the rate of CIN persistence as higher than previously believed among individuals with BC, this study provides novel insights into the functional deficits associated with persistent CIN in this population. We calculated the rate of postural control deficits to be 85% [80%, 90%] among those who presented for in-person biomechanical testing. Therefore, of the ~\u0026thinsp;85% of individuals in this cohort who reported persistent CIN, approximately 85% demonstrated quantifiable balance deficits in addition to patient-reported sensory symptoms. Because postural control dysfunction predicts increased fall risk, independent of sensory symptoms (Maki et al., \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e1994\u003c/span\u003e; Worthen-Chaudhari et al., \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e2018\u003c/span\u003e), this high rate of postural control dysfunction represents a potential neuromotor mechanism underlying the increased fall risk of individuals with CIN (Bao et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Winters-Stone et al., \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Postural control deficits can be added to known functional consequences of CIN, in addition to known deficits in dual-task performance (Worthen-Chaudhari et al., \u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e2024\u003c/span\u003e), gait characteristics (i.e., shorter and slower steps), chair-stand test, and short physical performance battery (Winters-Stone et al., \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e2017\u003c/span\u003e). There remains a need for more prospective studies characterizing the nature, scope, and mechanisms underlying functional deficits resulting from CIN. These should measure CIN symptoms using mixed-methods that combine patient-reported outcomes of sensation with quantitatively measured function.\u003c/p\u003e \u003cp\u003eThere are at least two ways in which the belief that CIN resolves spontaneously for most individuals with breast cancer may have developed. Firstly, very little literature has focused on breast cancer, specifically. Instead, most original research of CIN resolution rates after treatment tends to group CIN from different types of cancers together. For instance, a meta-analysis and systematic review by Seretny et al. (\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e2014\u003c/span\u003e) pooled data from 4179 individuals who received chemotherapy of any type for any cancer diagnosis. In this meta-analysis, approximately half of those diagnosed with CIN reported that the condition improved between 3- and 6-months post chemotherapy completion. It is possible that results were assumed to generalize to individuals with BC.\u003c/p\u003e \u003cp\u003eA second way that the belief of spontaneous CIN resolution may have developed is through misinterpretation of the original data. We found that two original data sets, from Postma et al (\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e1995\u003c/span\u003e) and Osmani et al (\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e2012\u003c/span\u003e), are cited to substantiate this interpretation. However, neither dataset supports the idea of spontaneous, complete resolution within 3 months.\u003c/p\u003e \u003cp\u003ePostma et al. (\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e1995\u003c/span\u003e) followed 7 individuals with BC; all 7 developed symptoms within their first course of high-dose paclitaxel. The authors followed 5 of these individuals for 9 months post chemotherapy termination, finding that 3 of 5 reported complete resolution of pain; all 5 reported changing CIN sensation in the 9 months following chemotherapy termination; however, none reported complete resolution of symptoms such as numbness, tingling, or functional deficits. Based on these results, Postma et al. (\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e1995\u003c/span\u003e) conclude that CIN is \u0026ldquo;at least partially reversible\u0026rdquo; after discontinuation of paclitaxel exposure but the authors do not interpret their results to mean that spontaneous, complete resolution occurs for a majority within 6 months (Postma et al., \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e1995\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe second dataset cited to substantiate the claim of CIN spontaneous resolution is published in Osmani et al. (\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e2012\u003c/span\u003e) \u0026ldquo;Taxane-based neuropathy has a good long-term prognosis: a 1 to 13 year evaluation\u0026rdquo;. Within this dataset, only 6 of those diagnosed with CIN, or 14% or those surveyed, reported complete recovery within the 6 months following taxane-based treatment completion. Based on limited relative improvement, reported retrospectively by 86% of those with persistent CIN, the authors conclude that long-term prognosis for complete symptom resolution is good (Osmani et al., \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e2012\u003c/span\u003e) and infer that a majority experience spontaneous resolution. Of note, more than 80% of participants in this study were treated with docetaxel alone, yet results are generalized to all taxane-based CIN diagnoses. Interestingly, a close look at the data in these original reports substantiates our current estimate of CIN persistence among approximately 85%. Osmani et al (\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e2012\u003c/span\u003e) report that 86% reported persistence of symptoms, albeit at a reduced severity to initial onset, and only 14% reported complete, spontaneous resolution of CIN. These original studies, cited to support the belief that CIN spontaneously resolves for a majority, ultimately support our current finding of chronic symptom persistence among approximately 85% of individuals with BC who developed CIN during chemotherapy treatment.\u003c/p\u003e"},{"header":"Limitations","content":"\u003cp\u003eWhile our study provides valuable insights into CIN persistence, limitations should be considered. For instance, our identification of those who reported CIN symptoms during treatment was limited to individuals detected via retrospective semantic search of electronic medical records. Because the text describing CIN in patient charts is not standardized across providers and years, the key terms describing CIN symptoms and diagnosis might have changed over the 9 year period within which we searched and between the different providers who we worked with to complete this survey. Therefore, our results may underestimate the incidence of those who developed CIN during treatment. Conversely, selection bias may have affected who responded to our survey, such that clients who felt better may have responded less frequently to our survey than those who felt worse, skewing estimates toward worse outcomes. Although this possibility is accounted for by our sensitivity analysis, it is important to note. Additionally, this data set is limited in that we confirm persistence of symptoms but lack the ability to confirm consistency of specific symptoms over the period of time between onset and time of survey. Postma et al (\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e1995\u003c/span\u003e) provided initial evidence that neuropathic presentation of chronic CIN changes over time such that presence of symptomatology is consistent, but characteristics of symptoms may be dynamic. Additionally, more recent evidence suggests that neuropathic presentation of CIN might change over time, with one case report documenting a short period of resolution between 3 and 6 months post-chemotherapy completion followed by reemergence of tingling and coldness symptoms in the 2\u0026ndash;6 years post chemotherapy completion (Papautsky et al.). Among individuals with BC, future research should use a repeated measures design over at least 5 years to characterize the changes in CIN symptoms post completion of chemotherapy.\u003c/p\u003e \u003cp\u003eDespite these limitations, we found that most individuals with BC and CIN \u0026ndash; almost 6 in 7 \u0026ndash; experience persistent CIN symptoms its that do not spontaneously resolve within 3 months amd that a majority of these individuals also demonstrate neuromotor dysfunction. Given the impact of CIN on wellness in survivorship (Lustberg et al., \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e2023\u003c/span\u003e), there is a need to develop and implement targeted interventions to improve symptoms, function, and quality of life for affected individuals. Our findings reinforce the urgent need for routine long-term follow-up and neurorehabilitation strategies to address the burden of chronic CIN among BC survivors. More research is needed to characterize the dynamics of CIN symptoms through survivorship (Papautsky et al., in press; Postma et al., \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e1995\u003c/span\u003e) and determine best practices to prevent and mitigate this condition that sits at the intersection of oncologic, neurologic, and rehabilitative medicine.\u003c/p\u003e"},{"header":"Declarations","content":" \u003cp\u003e \u003cstrong\u003eEthical Approval and Consent to participate\u003c/strong\u003e \u003cp\u003e The study was approved by The Ohio State University Institutional Review Board (Ref: 2014C0177), and informed consent was obtained from all participants before the study, in accordance with the Declaration of Helsinki\u003c/p\u003e \u003c/p\u003e\u003cp\u003e \u003ch2\u003eConsent for publication\u003c/h2\u003e \u003cp\u003eAuthors grant Springer exclusive rights to publish, distribute, and archive the work in all media and confirm the work is original, not previously published, and doesn\u0026rsquo;t infringe on others\u0026rsquo; rights. No protected health information or images are included in this publication.\u003c/p\u003e \u003c/p\u003e\u003cp\u003e \u003ch2\u003eCompeting interests\u003c/h2\u003e \u003cp\u003eThe authors declare they have no competing interests.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eFunding\u003c/h2\u003e \u003cp\u003eThis study was supported by National Institute on Aging (NIA) awards R21-AG068831 and R01-AG084676.\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003ePMS conceived of the study and led design of the study, data analysis in R, and interpretation of the data with LWC.LWC designed data acquisition, led manuscript writing, and contributed to design of the study and interpretation of the data with PMS.BL contributed to drafting and revising the manuscript as well as interpretation, validation, and collation of acquired data.MBL contributed to design of the study, interpretation of the data, and substantive revision of the work.MGM, SS, APD contributed to data acquisition, interpretation of the data, and substantive revision of the work.All authors read and approved the final manuscript.\u003c/p\u003e\u003ch2\u003eAcknowledgement\u003c/h2\u003e\u003cp\u003eWe thank Kristin Lantis, Jackie Wilder, and Courtney Bland for data collection efforts on this project including survey administration.\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003eData are available in supplementary files associated with this manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eArgyriou AA, Velasco R, Kalofonou F, Litsardopoulos P, Alemany M, Rikos D, Kalofonos HP, Bruna J. Gender and age effects on the incidence and severity of chemotherapy-induced neuropathic pain: A propensity score matching analysis. BMC Cancer. 2025;25(1):1193. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s12885-025-14579-x\u003c/span\u003e\u003cspan address=\"10.1186/s12885-025-14579-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327\u0026ndash;33. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s10549-016-3939-0\u003c/span\u003e\u003cspan address=\"10.1007/s10549-016-3939-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCavaletti G, Alberti P, Marmiroli P. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: An Underdiagnosed Clinical Entity? Am Soc Clin Oncol Educational Book. 2015;35:e553\u0026ndash;60. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.14694/EdBook_AM.2015.35.e553\u003c/span\u003e\u003cspan address=\"10.14694/EdBook_AM.2015.35.e553\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDonker SF, Ledebt A, Roerdink M, Savelsbergh GJ, Beek PJ. Children with cerebral palsy exhibit greater and more regular postural sway than typically developing children. Exp Brain Res. 2008;184(3):363\u0026ndash;70.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDonker SF, Roerdink M, Greven AJ, Beek PJ. Regularity of center-of-pressure trajectories depends on the amount of attention invested in postural control. Exp Brain Res. 2007;181(1):1\u0026ndash;11.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFino PC, Horak FB, El-Gohary M, Guidarelli C, Medysky ME, Nagle SJ, Winters-Stone KM. Postural sway, falls, and self-reported neuropathy in aging female cancer survivors. Gait Posture. 2019;69:136\u0026ndash;42. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.gaitpost.2019.01.025\u003c/span\u003e\u003cspan address=\"10.1016/j.gaitpost.2019.01.025\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Recent Developments of Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral Neuropathy. Clin Cancer Res. 2019;25(21):6295\u0026ndash;301. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1158/1078-0432.CCR-18-2152\u003c/span\u003e\u003cspan address=\"10.1158/1078-0432.CCR-18-2152\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang MH. Screening and Examination of Fall Risk in Older Cancer Survivors. Rehabilitation Oncol. 2019;37(2):E7\u0026ndash;9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1097/01.REO.0000000000000166\u003c/span\u003e\u003cspan address=\"10.1097/01.REO.0000000000000166\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 2012;291(1\u0026ndash;3):1\u0026ndash;9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.tox.2011.10.019\u003c/span\u003e\u003cspan address=\"10.1016/j.tox.2011.10.019\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLantis K, Schnell P, Bland CR, Wilder J, Hock K, Vargo C, Glover NA, Hackney ME, Lustberg MB, Worthen-Chaudhari L. Biomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: Study protocol for a randomized controlled trial and preliminary baseline data. Trials. 2023;24(1):564. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s13063-023-07554-z\u003c/span\u003e\u003cspan address=\"10.1186/s13063-023-07554-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res. 2013;22(10):2787\u0026ndash;99. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s11136-013-0379-8\u003c/span\u003e\u003cspan address=\"10.1007/s11136-013-0379-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi Y, Lustberg MB, Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers. 2021;13(4):766. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3390/cancers13040766\u003c/span\u003e\u003cspan address=\"10.3390/cancers13040766\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLoprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325\u0026ndash;48. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1200/JCO.20.01399\u003c/span\u003e\u003cspan address=\"10.1200/JCO.20.01399\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLustberg MB, Kuderer NM, Desai A, Bergerot C, Lyman GH. Mitigating long-term and delayed adverse events associated with cancer treatment: Implications for survivorship. Nat Rev Clin Oncol. 2023;20(8):527\u0026ndash;42. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41571-023-00776-9\u003c/span\u003e\u003cspan address=\"10.1038/s41571-023-00776-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaih\u0026ouml;fner C, Diel I, Tesch H, Quandel T, Baron R. Chemotherapy-induced peripheral neuropathy (CIPN): Current therapies and topical treatment option with high-concentration capsaicin. Support Care Cancer. 2021;29(8):4223\u0026ndash;38. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s00520-021-06042-x\u003c/span\u003e\u003cspan address=\"10.1007/s00520-021-06042-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMaki BE, Holliday PJ, Topper AK. A Prospective Study of Postural Balance and Risk of Falling in an Ambulatory and Independent Elderly Population. J Gerontology: Med Sci. 1994;49(2):72\u0026ndash;84.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, Lustberg MB. Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy. Curr Treat Options Oncol. 2022;23(1):29\u0026ndash;42. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s11864-021-00926-0\u003c/span\u003e\u003cspan address=\"10.1007/s11864-021-00926-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMiltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014;40(7):872\u0026ndash;82. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.ctrv.2014.04.004\u003c/span\u003e\u003cspan address=\"10.1016/j.ctrv.2014.04.004\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMo H, Yan X, Zhao F, Teng Y, Sun X, Lv Z, Cao M, Zhao J, Song G, Pan B, Li H, Zhai J, Xu B, Ma F. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer. JAMA Netw Open. 2022;5(11):e2239788. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1001/jamanetworkopen.2022.39788\u003c/span\u003e\u003cspan address=\"10.1001/jamanetworkopen.2022.39788\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMonfort S, Pan X, Loprinzi CL, Lustberg MB, Chaudhari AMW. Exploring the Roles of Central and Peripheral Nervous System Function in Gait Stability: Preliminary Insights from Cancer Survivors. Gait Posture. 2019;71:62\u0026ndash;8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.gaitpost.2019.04.002\u003c/span\u003e\u003cspan address=\"10.1016/j.gaitpost.2019.04.002\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMonfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton MJ, Loprinzi CL, Chaudhari AMW, Lustberg MB. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Res Treat. 2017;164(1):69\u0026ndash;77. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s10549-017-4230-8\u003c/span\u003e\u003cspan address=\"10.1007/s10549-017-4230-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMonfort S, Pan X, Patrick R, Singaravelu J, Loprinzi CL, Lustberg MB, Chaudhari AMW. Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study. Gait Posture. 2016;48:237\u0026ndash;42. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.gaitpost.2016.06.011\u003c/span\u003e\u003cspan address=\"10.1016/j.gaitpost.2016.06.011\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOsmani K, Vignes S, Aissi M, Wade F, Milani P, L\u0026eacute;vy BI, Kubis N. Taxane-induced peripheral neuropathy has good long-term prognosis: A 1- to 13-year evaluation. J Neurol. 2012;259(9):1936\u0026ndash;43. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s00415-012-6442-5\u003c/span\u003e\u003cspan address=\"10.1007/s00415-012-6442-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePapautsky EL, Lustberg MB, Worthen-Chaudhari LC. (in press). Change in Presentation of Chemotherapy-induced Neuropathy over a 6-year Period Post Treatment: A Case Study. \u003cem\u003eArchives of Physical Medicine and Rehabilitation\u003c/em\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePostma TJ, Vermorken JB, Liefting AJM, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol. 1995;6(5):489\u0026ndash;94. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.sciencedirect.com/science/article/pii/S0923753419612366\u003c/span\u003e\u003cspan address=\"https://www.sciencedirect.com/science/article/pii/S0923753419612366\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePrieto TE, Myklebust JB, Hoffmann RG, Lovett EG, Myklebust BM. Measures of postural steadiness differences between healthy young and elderly adults. Trans Biomedical Eng. 1996;43(9):965\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eQuatman-Yates CC, Bonnette MS, Hugentobler JA, M\u0026eacute;d\u0026eacute; MB, Kiefer AW, Kurowski BG, Riley MA. Postconcussion postural sway variability changes in youth: The benefit of structural variability analyses. Pediatr Phys Ther. 2015;27(4):316.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eReed CA, Chaudhari AM, Worthen-Chaudhari LC, Bigelow KE, Monfort SM. (2020). A new perspective on transient characteristics of quiet stance postural control. PLoS ONE, 15(8), e0237246.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRoerdink M, Hlavackova P, Vuillerme N. Center-of-pressure regularity as a marker for attentional investment in postural control: A comparison between sitting and standing postures. Hum Mov Sci. 2011;30(2):203\u0026ndash;12.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSeretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. PAIN\u0026reg;. 2014;155(12):2461\u0026ndash;70. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.pain.2014.09.020\u003c/span\u003e\u003cspan address=\"10.1016/j.pain.2014.09.020\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSong SJ, Min J, Suh SY, Jung SH, Hahn HJ, Im S-A, Lee J-Y. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer. 2017;25(7):2241\u0026ndash;8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s00520-017-3631-x\u003c/span\u003e\u003cspan address=\"10.1007/s00520-017-3631-x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStins JF, Michielsen ME, Roerdink M, Beek PJ. Sway regularity reflects attentional involvement in postural control: Effects of expertise, vision and cognition. Gait Posture. 2009;30(1):106\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTanay MAL, Armes J, Ream E. (2017). The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: A qualitative thematic synthesis. Eur J Cancer Care, 26(5), e12443.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWechsler S, Wood L. The Effect of Chemotherapy on Balance, Gait, and Falls Among Cancer Survivors: A Scoping Review. Rehabilitation Oncol. 2021;39(1):6\u0026ndash;22. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1097/01.REO.0000000000000238\u003c/span\u003e\u003cspan address=\"10.1097/01.REO.0000000000000238\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWinters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;35(23):2604. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549452/\u003c/span\u003e\u003cspan address=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549452/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWinters-Stone KM, Krasnow SM, Horak FB, Mancini M, Cameron MH, Dieckmann NF, Stoyles SA, Roeland EJ. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: The PATTERN observational study protocol (NCT05790538). BMC Cancer. 2023;23(1):1087. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s12885-023-11546-2\u003c/span\u003e\u003cspan address=\"10.1186/s12885-023-11546-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWorthen-Chaudhari L, Crasta JE, Schnell PM, Lantis K, Martis J, WIlder J, Bland CR, Hackney ME, Lustberg MB. (2024). Neurologic Dance Training (NDT) and home exercise improve motor-cognitive integration comparably, but differently, among breast cancer survivors with chemotherapy-induced neuropathy: Initial results of a randomized, controlled clinical trial. J Alzheimer\u0026rsquo;s Disease, 13872877241291440.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWorthen-Chaudhari L, Monfort S, Bland C, Pan X, Chaudhari A. Characterizing within-subject variability in quantified measures of balance control: A cohort study. Gait Posture. 2018;64:141\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"breast-cancer-research","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"brcr","sideBox":"Learn more about [Breast Cancer Research](http://breast-cancer-research.biomedcentral.com)","snPcode":"13058","submissionUrl":"https://submission.nature.com/new-submission/13058/3","title":"Breast Cancer Research","twitterHandle":"@BCRJournal","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-8594232/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8594232/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003ePurpose\u003c/h2\u003e \u003cp\u003eA majority of individuals treated with taxane agents for breast cancer (BC) develop chemotherapy-induced neuropathy (CIN) yet questions remain regarding long-term prognosis of this neurologic complication. We sought to characterize CIN chronicity in terms of persistence rate, predictors, and neuromotor dysfunction.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eWe surveyed individuals with BC who developed CIN during taxane exposure at least 3 months prior. We calculated the proportion of survey respondents with/without chronic CIN symptoms and performed a sensitivity analysis, computing the largest and smallest possible rate of CIN chronicity given the number of non-respondents. Additionally, we analyzed predictors of chronicity (e.g., age, hgA1c level) and characterized the proportion of individuals with chronic sensory symptoms who also demonstrated neuromotor dysfunction.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eWe surveyed two hundred and fifty-eight individuals (99.2% female). Mean(SD) age\u0026thinsp;=\u0026thinsp;60.5(11.1); time since last taxane exposure\u0026thinsp;=\u0026thinsp;3.25(2.38) years; and A1C\u0026thinsp;=\u0026thinsp;5.64(0.607). Persistent CIN sensory symptoms were reported by 84.9% [95% CI 79.5%, 90.3%]. Accounting for both the non-response sensitivity analysis and statistical uncertainty, we calculate bounds for the CIN persistence rate to be no lower than 50.5% and no higher than 93.6%. Variables predictive of CIN chronicity included high A1C (p\u0026thinsp;=\u0026thinsp;0.037). Variables not predictive included total chemotherapy dose (p\u0026thinsp;=\u0026thinsp;0.8); race (white vs non-white, p\u0026thinsp;=\u0026thinsp;0.4); age (p\u0026thinsp;=\u0026thinsp;0.09); time since last taxane exposure\u0026thinsp;\u0026lt;\u0026thinsp;6 years (p\u0026thinsp;=\u0026thinsp;0.051). Among those with chronic CIN, 85% demonstrated quantifiable neuromotor dysfunction.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eCIN symptoms persist chronically for most individuals (~\u0026thinsp;85%) with breast cancer who develop the condition during taxane treatment. Novel interventions are needed to alleviate sensory symptoms and associated neuromotor dysfunction.\u003c/p\u003e","manuscriptTitle":"Chemotherapy-induced neuropathy (CIN) persists chronically for most individuals with breast cancer who develop the condition: A survey study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-01-28 20:13:58","doi":"10.21203/rs.3.rs-8594232/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2026-04-15T00:18:59+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-03-15T06:45:32+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"243054867224732799216840367813141125568","date":"2026-03-01T21:47:22+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"266035730325011336913392281324306274361","date":"2026-02-28T15:31:28+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"23233186062948951656905598186667938550","date":"2026-01-26T21:44:37+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2026-01-22T01:24:54+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2026-01-21T01:02:08+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2026-01-21T00:42:27+00:00","index":"","fulltext":""},{"type":"submitted","content":"Breast Cancer Research","date":"2026-01-13T16:14:06+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"breast-cancer-research","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"brcr","sideBox":"Learn more about [Breast Cancer Research](http://breast-cancer-research.biomedcentral.com)","snPcode":"13058","submissionUrl":"https://submission.nature.com/new-submission/13058/3","title":"Breast Cancer Research","twitterHandle":"@BCRJournal","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"7647d5d8-0b12-43c1-9ce9-b002d3b9c2eb","owner":[],"postedDate":"January 28th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"in-revision","subjectAreas":[],"tags":[],"updatedAt":"2026-04-15T00:24:02+00:00","versionOfRecord":[],"versionCreatedAt":"2026-01-28 20:13:58","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8594232","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8594232","identity":"rs-8594232","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}